Quinolones, are a class of widely used and popular powerful antibiotics with broad coverage. RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski, recently published a series of three papers on investigating the risk of acute liver failure (ALF) following systemic administration of quinolones, based on a synthesis of evidence from available clinical trials, the US FDA Adverse Event Reporting System (FAERS), and a large US database of electronic health records (EHR).
Although clinical trials provided little evidence of an increased risk, there were reports in FAERS of quinolone-linked ALF cases. Although the primary EHR analysis did not reveal an overall association between quinolones as a class and ALF risk, a possible risk was identified among those with no or few comorbidities, those ≤ 60 years of age, women, men, African Americans, and Caucasians.
The authors noted that elevated risks seen in some subgroups warrant further investigation.
More RSI News
Working with the College of Physicians and Surgeons of Alberta, Risk Sciences International conducted a wide-ranging review of aging and cognitive decline, with specific focus…
Read News Item
Working with international thought leaders in risk science, Risk Sciences International investigators contributed to the development of the evidenced-based risk assessment framework shown in the…
Read News Item
Problem Formulation in Food Safety Assessments conducted by the European Food Safety Authority RSI investigators recently provided advise to the European Food Safety Authority (EFSA)…
Read News Item
In its 2007 report on Toxicity Testing in the 21st Century: A Vision and a Strategy, the US National Research Council (NRC) highlighted need for more rapid…
Read News Item